MML Investors Services’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-9,504
| Closed | -$382K | – | 3262 |
|
|
2026
Q1 | $382K | Buy |
+9,504
| New | +$205K | ﹤0.01% | 2390 |
|
|
2024
Q4 | – | Sell |
-13,631
| Closed | -$393K | – | 2662 |
|
|
2024
Q3 | $393K | Sell |
13,631
-1,519
| -10% | -$56.3K | ﹤0.01% | 2012 |
|
|
2024
Q2 | $581K | Buy |
15,150
+2,854
| +23% | +$129K | ﹤0.01% | 1693 |
|
|
2024
Q1 | $723K | Buy |
12,296
+2,168
| +21% | +$138K | ﹤0.01% | 1598 |
|
|
2023
Q4 | $606K | Buy |
10,128
+1,759
| +21% | +$89.2K | ﹤0.01% | 1639 |
|
|
2023
Q3 | $318K | Buy |
8,369
+976
| +13% | +$42.9K | ﹤0.01% | 1891 |
|
|
2023
Q2 | $674K | Buy |
7,393
+1,191
| +19% | +$103K | ﹤0.01% | 1449 |
|
|
2023
Q1 | $409K | Buy |
6,202
+2,172
| +54% | +$125K | ﹤0.01% | 1511 |
|
|
2022
Q4 | $208K | Sell |
4,030
-201
| -5% | -$10.7K | ﹤0.01% | 2007 |
|
|
2022
Q3 | $289K | Buy |
+4,231
| New | +$250K | ﹤0.01% | 1700 |
|
|
2022
Q2 | – | Sell |
-7,892
| Closed | -$401K | – | 2032 |
|
|
2022
Q1 | $401K | Buy |
7,892
+1
| +0% | +$44 | ﹤0.01% | 1571 |
|
|
2021
Q4 | $373K | Sell |
7,891
-79
| -1% | -$3.11K | ﹤0.01% | 1567 |
|
|
2021
Q3 | $263K | Buy |
7,970
+354
| +5% | +$19.9K | ﹤0.01% | 1705 |
|
|
2021
Q2 | $481K | Buy |
7,616
+6
| +0.1% | +$310 | ﹤0.01% | 1350 |
|
|
2021
Q1 | $327K | Buy |
7,610
+30
| +0.4% | +$1.42K | ﹤0.01% | 1467 |
|
|
2020
Q4 | $434K | Hold |
7,580
| – | – | ﹤0.01% | 1226 |
|
|
2020
Q3 | $229K | Hold |
7,580
| – | – | ﹤0.01% | 1420 |
|
|
2020
Q2 | $248K | Buy |
+7,580
| New | +$243K | ﹤0.01% | 1310 |
|
Other funds holding APLS
MML Investors Services's APLS Position: Q2 2026 in Review
MML Investors Services sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 9,504 shares — an estimated $382K sold.
MML Investors Services first reported a position in APLS in Q2 2020 and held it in 18 quarters. The position peaked at $723K in Q1 2024. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- MML Investors Services reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- MML Investors Services sold 9,504 Apellis Pharmaceuticals shares in Q2 2026, an estimated $382K.
- MML Investors Services first reported a position in Apellis Pharmaceuticals in Q2 2020 and held it in 18 quarters.
- MML Investors Services's Apellis Pharmaceuticals position peaked at $723K in Q1 2024.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on MML Investors Services's 13F filing for Q2 2026, filed 7 Aug 2026.